Xenetic Biosciences Inc (NASDAQ:XBIO – Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 16,800 shares, an increase of 460.0% from the September 30th total of 3,000 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 1.3% of the shares of the stock are short sold.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a research note on Tuesday, August 20th.
Read Our Latest Analysis on XBIO
Xenetic Biosciences Trading Up 2.8 %
Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83). The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.54 million. Xenetic Biosciences had a negative net margin of 186.39% and a negative return on equity of 51.05%. On average, equities analysts predict that Xenetic Biosciences will post -1.01 EPS for the current year.
About Xenetic Biosciences
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
See Also
- Five stocks we like better than Xenetic Biosciences
- P/E Ratio Calculation: How to Assess Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Use the MarketBeat Dividend Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Why Are Stock Sectors Important to Successful Investing?
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.